S&P 500   3,271.88 (+0.78%)
DOW   26,954.22 (+0.52%)
QQQ   269.23 (+1.45%)
AAPL   110.87 (+2.45%)
MSFT   206.90 (+1.83%)
FB   251.29 (+0.71%)
GOOGL   1,429.13 (+0.44%)
AMZN   3,056.99 (+1.23%)
TSLA   403.26 (+3.99%)
NVDA   507.40 (+2.73%)
BABA   268.06 (-0.62%)
CGC   14.04 (-1.61%)
GE   6.08 (+0.33%)
MU   48.77 (-1.41%)
AMD   77.25 (+1.89%)
T   27.90 (-0.50%)
F   6.53 (-1.95%)
ACB   5.01 (-3.65%)
GILD   61.99 (-0.42%)
NFLX   476.61 (+0.75%)
DIS   122.95 (+0.38%)
BAC   23.34 (+0.00%)
BA   152.56 (+4.46%)
S&P 500   3,271.88 (+0.78%)
DOW   26,954.22 (+0.52%)
QQQ   269.23 (+1.45%)
AAPL   110.87 (+2.45%)
MSFT   206.90 (+1.83%)
FB   251.29 (+0.71%)
GOOGL   1,429.13 (+0.44%)
AMZN   3,056.99 (+1.23%)
TSLA   403.26 (+3.99%)
NVDA   507.40 (+2.73%)
BABA   268.06 (-0.62%)
CGC   14.04 (-1.61%)
GE   6.08 (+0.33%)
MU   48.77 (-1.41%)
AMD   77.25 (+1.89%)
T   27.90 (-0.50%)
F   6.53 (-1.95%)
ACB   5.01 (-3.65%)
GILD   61.99 (-0.42%)
NFLX   476.61 (+0.75%)
DIS   122.95 (+0.38%)
BAC   23.34 (+0.00%)
BA   152.56 (+4.46%)
S&P 500   3,271.88 (+0.78%)
DOW   26,954.22 (+0.52%)
QQQ   269.23 (+1.45%)
AAPL   110.87 (+2.45%)
MSFT   206.90 (+1.83%)
FB   251.29 (+0.71%)
GOOGL   1,429.13 (+0.44%)
AMZN   3,056.99 (+1.23%)
TSLA   403.26 (+3.99%)
NVDA   507.40 (+2.73%)
BABA   268.06 (-0.62%)
CGC   14.04 (-1.61%)
GE   6.08 (+0.33%)
MU   48.77 (-1.41%)
AMD   77.25 (+1.89%)
T   27.90 (-0.50%)
F   6.53 (-1.95%)
ACB   5.01 (-3.65%)
GILD   61.99 (-0.42%)
NFLX   476.61 (+0.75%)
DIS   122.95 (+0.38%)
BAC   23.34 (+0.00%)
BA   152.56 (+4.46%)
S&P 500   3,271.88 (+0.78%)
DOW   26,954.22 (+0.52%)
QQQ   269.23 (+1.45%)
AAPL   110.87 (+2.45%)
MSFT   206.90 (+1.83%)
FB   251.29 (+0.71%)
GOOGL   1,429.13 (+0.44%)
AMZN   3,056.99 (+1.23%)
TSLA   403.26 (+3.99%)
NVDA   507.40 (+2.73%)
BABA   268.06 (-0.62%)
CGC   14.04 (-1.61%)
GE   6.08 (+0.33%)
MU   48.77 (-1.41%)
AMD   77.25 (+1.89%)
T   27.90 (-0.50%)
F   6.53 (-1.95%)
ACB   5.01 (-3.65%)
GILD   61.99 (-0.42%)
NFLX   476.61 (+0.75%)
DIS   122.95 (+0.38%)
BAC   23.34 (+0.00%)
BA   152.56 (+4.46%)
Log in
NYSE:MOR

MorphoSys News Headlines

$31.08
+0.37 (+1.20 %)
(As of 09/25/2020 11:56 AM ET)
Add
Compare
Today's Range
$31.05
Now: $31.08
$31.08
50-Day Range
$30.28
MA: $31.74
$34.74
52-Week Range
$18.21
Now: $31.08
$37.96
Volume121 shs
Average Volume116,112 shs
Market Capitalization$4.09 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

MorphoSys (NYSE MOR) News Headlines Today

Source:
DateHeadline
MorphoSys (NYSE:MOR) Trading Down 0.4%MorphoSys (NYSE:MOR) Trading Down 0.4%
americanbankingnews.com - September 16 at 1:22 AM
Biotech Report: MorphoSys (MOR) und MagForce sacken abBiotech Report: MorphoSys (MOR) und MagForce sacken ab
finanznachrichten.de - September 9 at 4:12 AM
MorphoSys reports 1H resultsMorphoSys reports 1H results
seekingalpha.com - August 5 at 8:44 PM
MorphoSys Posts Wider Loss In Q2, Revenues Down 47%; Confirms 2020 GuidanceMorphoSys Posts Wider Loss In Q2, Revenues Down 47%; Confirms 2020 Guidance
nasdaq.com - August 5 at 8:44 PM
MorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of BiopharmaMorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - August 3 at 12:36 PM
Xencor gets $25M milestone payment from MorphoSysXencor gets $25M milestone payment from MorphoSys
seekingalpha.com - August 2 at 2:49 PM
FDA OKs Incyte/Morphosys tafasitamab for treatment-resistant lymphomaFDA OKs Incyte/Morphosys' tafasitamab for treatment-resistant lymphoma
seekingalpha.com - August 1 at 8:50 AM
MorphoSys-Aktie leicht im PlusMorphoSys-Aktie leicht im Plus
www.finanznachrichten.de - July 31 at 10:49 PM
Biotech Report: Sektor schwächer, MorphoSys (MOR) geben wieder ab, Gilead Sciences (GILD) verlierenBiotech Report: Sektor schwächer, MorphoSys (MOR) geben wieder ab, Gilead Sciences (GILD) verlieren
www.finanznachrichten.de - July 31 at 10:49 PM
FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
finance.yahoo.com - July 31 at 10:49 PM
MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
finance.yahoo.com - July 31 at 10:49 PM
FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
finance.yahoo.com - July 31 at 10:49 PM
wikifolio whispers p.m. zu BASF, Deutsche Wohnen, MorphoSys ...wikifolio whispers p.m. zu BASF, Deutsche Wohnen, MorphoSys ...
www.finanznachrichten.de - July 30 at 3:36 PM
Aktienmarkt: Aktie von MorphoSys kann sich nicht behauptenAktienmarkt: Aktie von MorphoSys kann sich nicht behaupten
www.finanznachrichten.de - July 30 at 3:36 PM
Sjogren’s Syndrome Pipeline Insights, 2020Sjogren’s Syndrome Pipeline Insights, 2020
www.marketwatch.com - July 19 at 10:47 PM
Galapagos NV: Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patientsGalapagos NV: Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
www.bloomberg.com - July 15 at 12:57 AM
FDA Approves Janssens Tremfya For Treatment Of Adults With Active Psoriatic ArthritisFDA Approves Janssen's Tremfya For Treatment Of Adults With Active Psoriatic Arthritis
www.nasdaq.com - July 15 at 12:57 AM
Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock MarketNasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
www.bloomberg.com - July 9 at 9:39 PM
MorphoSys AG: MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for TafasitamabMorphoSys AG: MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab
www.finanznachrichten.de - May 21 at 7:45 AM
MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab (news with additional features)MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab (news with additional features)
uk.finance.yahoo.com - May 20 at 8:48 PM
Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for TafasitamabIncyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab
www.businesswire.com - May 20 at 3:46 PM
EMA accepts MorphoSys application for tafasitamab for type of blood cancerEMA accepts MorphoSys application for tafasitamab for type of blood cancer
seekingalpha.com - May 20 at 3:46 PM
MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings (news with additional features)MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings (news with additional features)
uk.finance.yahoo.com - May 15 at 12:03 AM
MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL (news with additional features)MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL (news with additional features)
uk.finance.yahoo.com - May 15 at 12:03 AM
MorphoSys up 3% on long-term tafasitamab data in blood cancerMorphoSys up 3% on long-term tafasitamab data in blood cancer
seekingalpha.com - May 14 at 1:59 PM
BRIEF-Morphosys And Incyte Announce Follow-Up Results From Study Of TafasitamabBRIEF-Morphosys And Incyte Announce Follow-Up Results From Study Of Tafasitamab
www.reuters.com - May 14 at 1:59 PM
MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual MeetingsMorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings
finance.yahoo.com - May 14 at 1:59 PM
Hematological Malignancies Disease Market 2020 by Regions, Manufactures, Type, Application, Sales, Revenue and Forecast to 2026Hematological Malignancies Disease Market 2020 by Regions, Manufactures, Type, Application, Sales, Revenue and Forecast to 2026
www.marketwatch.com - May 11 at 9:18 AM
MorphoSys AG 2020 Q1 - Results - Earnings Call PresentationMorphoSys AG 2020 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 10 at 5:34 PM
Do Its Financials Have Any Role To Play In Driving MorphoSys AGs (ETR:MOR) Stock Up Recently?Do Its Financials Have Any Role To Play In Driving MorphoSys AG's (ETR:MOR) Stock Up Recently?
finance.yahoo.com - May 9 at 4:28 PM
BRIEF-Morphosys Reports Q1 Revenue 251.2 Mln EUR Versus 13.5 Mln EUR Year AgoBRIEF-Morphosys Reports Q1 Revenue 251.2 Mln EUR Versus 13.5 Mln EUR Year Ago
www.reuters.com - May 7 at 8:11 AM
DGAP-News: MorphoSys Reports First Quarter 2020 ResultsDGAP-News: MorphoSys Reports First Quarter 2020 Results
www.bloomberg.com - May 6 at 6:27 PM
MorphoSys Reports Profit In Q1; Affirms Guidance - Quick FactsMorphoSys Reports Profit In Q1; Affirms Guidance - Quick Facts
www.nasdaq.com - May 6 at 6:27 PM
MorphoSys Reports First Quarter 2020 ResultsMorphoSys Reports First Quarter 2020 Results
finance.yahoo.com - May 6 at 6:27 PM
Axsome Shares Jump 25% on Alzheimer's Study ResultsAxsome Shares Jump 25% on Alzheimer's Study Results
finance.yahoo.com - April 28 at 11:18 AM
I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in MainlandI-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland
www.bloomberg.com - April 27 at 6:40 PM
MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma inMorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in
www.bloomberg.com - April 27 at 6:40 PM
MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland ChinaMorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland China
finance.yahoo.com - April 27 at 6:40 PM
Is MorphoSys AG (MOR) Going to Burn These Hedge Funds?Is MorphoSys AG (MOR) Going to Burn These Hedge Funds?
finance.yahoo.com - April 6 at 10:00 PM
MorphoSys says coronavirus impacting clinical studies and businessMorphoSys says coronavirus impacting clinical studies and business
finance.yahoo.com - April 6 at 5:00 PM
BRIEF-Morphosys FY Revenue 71.8 Million EUR Versus 76.4 Million EUR Year AgoBRIEF-Morphosys FY Revenue 71.8 Million EUR Versus 76.4 Million EUR Year Ago
www.reuters.com - March 19 at 11:30 PM
MorphoSys AG 2019 Q4 - Results - Earnings Call PresentationMorphoSys AG 2019 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 19 at 1:28 PM
MorphoSys AG to Host Earnings CallMorphoSys AG to Host Earnings Call
finance.yahoo.com - March 19 at 1:28 PM
Invitation to MorphoSys Year-End Results 2019 Conference Call on March 19, 2020Invitation to MorphoSys' Year-End Results 2019 Conference Call on March 19, 2020
finance.yahoo.com - March 12 at 6:09 PM
Incyte wins OK to provide $750M payment for drug collaborationIncyte wins OK to provide $750M payment for drug collaboration
finance.yahoo.com - March 5 at 2:26 PM
MorphoSys, Incyte Receive Antitrust Clearance For Collaboration On TafasitamabMorphoSys, Incyte Receive Antitrust Clearance For Collaboration On Tafasitamab
www.nasdaq.com - March 3 at 11:04 PM
BRIEF-Morphosys, Incyte Announce Antitrust Clearance Of Global Collaboration And License Agreement For TafasitamabBRIEF-Morphosys, Incyte Announce Antitrust Clearance Of Global Collaboration And License Agreement For Tafasitamab
www.reuters.com - March 3 at 6:03 PM
Antitrust watchdog OK with MorphoSys - Incyte tafasitamab partnershipAntitrust watchdog OK with MorphoSys - Incyte tafasitamab partnership
seekingalpha.com - March 3 at 6:03 PM
MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for TafasitamabMorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab
finance.yahoo.com - March 3 at 6:03 PM
Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical ProgramsIncyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs
www.businesswire.com - February 13 at 9:11 AM
This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.